



# Interim Report – Q1-Q3, 2025

6 November 2025

 **ViroGates**

## Forward-looking statements

*Certain information set forth and given in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates’ business, projects and joint ventures; (iii) execution of ViroGates’ vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates’ projects; (v) completion of ViroGates’ projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates’ current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements.*

*Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.*

*These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.*

*Although forward-looking statements contained in this presentation are based upon what management of ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.*

# Contents

<b>Summary</b>	<b>4</b>
<b>Management review</b>	<b>8</b>
<b>Financial statements</b>	<b>13</b>
<b>Statement by the Board and Executive Management</b>	<b>22</b>

On 6 November 2025, the Board of Directors approved the interim report for the first nine months of 2025 (the period 1 January – 30 September 2025) for ViroGates A/S.

The interim report is unaudited.


# Contents

 <b>Summary</b>	<b>4</b>
Management review	8
Financial statements	13
Statement by the Board and Executive Management	22

# Q3 2025 revenue rose 49% Y-o-Y, offsetting lower Q2 performance and bringing total revenue for the first nine months slightly above Q1-Q3 2024

## Financial results in Q1-Q3, 2025 (Q1-Q3, 2024 results in brackets)

- Revenue increased by 4% to TDKK 3,542 (TDKK 3,396)
- Operating expenses decreased by 10% to TDKK -12,578 (TDKK -14,018)
- Operating loss decreased by 21% to TDKK -7,904 (TDKK -9,950)
- Net loss decreased by 20% to TDKK -7,961 (TDKK -9,918)
- Cash and cash equivalents at the end of the period amounted to TDKK 9,120 (TDKK 7,431)



*"We experienced a relatively stronger third quarter on the revenue side, with both recurring and new customers contributing to a 49% increase compared to the same period last year. However, this comes after a challenging second quarter, leaving total revenue for the first nine months of 2025 roughly in line with the same period in the previous year. With lower operating expenses and continued positive contributions from the Sobi work, our net loss has improved compared to last year."*

Josephine Baum Jørgensen, CFO



# In Q1–Q3 2025, ViroGates rolled out longevity campaigns, engaged in key conferences, and progressed POC+ development and Sobi collaboration

## Business highlights in Q1–Q3, 2025

- Participated in two conferences in Lithuania, incl. the Seimas Longevity Conference 2025 at the Lithuanian Parliament in Vilnius and the 3rd International Baltic Conference on Healthy Longevity, discussing longevity and healthy aging.
- Announced an amendment to the agreement with Swedish-based Sobi (Swedish Orphan Biovitrum AB (publ)) on developing suPARnostic® for commercial use in the US in combination with the pharmaceutical product Kineret® (anakinra).

*The amendment extends the collaboration between ViroGates and Sobi to include supporting Sobi's post-approval commitment with EMA for the suPARnostic® TurbiLatex' compliance with the new requirements of the EU IVDR. Thus, going forward, the scope of the agreement entails US and EU developments.*

- Participated in the Aesthetic & Anti-Aging Medicine World Congress 2025 in Monaco to promote suPARnostic® within the longevity segment.
- Announced achieved proof-of-concept for the further development of the suPARnostic® POC+ for the longevity testing market.
- Reported a recurring customer base of 18 customers (an increase from 16 recurring customers by the end of Q3 2024).



# The full-year financial guidance for 2025 is maintained at 5 to 7 DKKm in revenue and -8 and -11 DKKm in EBIT

## Full-year outlook, 2025

- The strategic refocusing that ViroGates is undergoing naturally entails uncertainty.
- The most recent quarter supports our redirected strategic focus on the longevity market. ViroGates is gaining increasing traction and interest at longevity conferences and is starting to see positive outcomes from its collaboration with suPAR Health LLC in the US longevity market. However, revenue contributions from longevity-focused customers remain at a modest level.
- ViroGates experiences continued high interest from the research community in suPARnostic®, but orders from this segment are historically of a volatile character and remain difficult to project.
- ViroGates continues to collaborate with Sobi to obtain marketing clearance for suPARnostic® TurbiLatex in the US. While the main project is expected to be finalized in 2025, it will not have a revenue effect until 2026 and beyond.
- The latest financial guidance for 2025, as communicated in Company Announcement No. 12-2024, published December 19, 2024, is maintained.

## Full-year financial guidance, 2025

**5 to 7 DKKm**

revenue in 2025

**-8 to -11 DKKm**

EBIT in 2025

# Contents

Summary	4
 Management review	8
Financial statements	13
Statement by the Board and Executive Management	22

# Revenue improved in Q3, but ViroGates still needs to gain more traction in the longevity market – with strong long-term expectations for the US



Jakob Knudsen

## Customer composition

Q3 brought higher revenue for ViroGates, and we are pleased to see existing longevity customers placing orders more frequently, while we are also adding new customers. We still have important work ahead to demonstrate a sustainable business, as we carefully balance maintaining our foothold in the acute care and research markets with an increasing focus to secure more recurring revenue in the longevity segment. Our core objective remains to establish suPARnostic® as the key biomarker for determining biological aging based on chronic inflammation.

## Collaboration with Sobi

We have continued our close collaboration with Sobi on a market clearance for suPARnostic® TurbiLatex in the US, announcing an amendment to the original agreement (cf. Company Announcement No. 2-2025 from March 19, 2025) in Q1, which extends the scope of the collaboration beyond the US market launch to also include compliance with EU IVDR requirements.

In Q3, ViroGates filed a 513(g) request with the US FDA to clarify the risk classification and, ultimately, the regulatory pathway required to obtain market clearance for suPARnostic® TurbiLatex in the US. We have also continued to advance the analytical and clinical validation in collaboration with partners in the US.

## suPARnostic® POC+ for longevity

As part of our transition into the health and longevity segment, we were pleased to report progress in our collaboration with GENSPEED Biotech on an improved version of the suPARnostic® POC+ product during Q2 2025 (cf. Company Announcement No. 9-2025 from June 16, 2025). The initial results were encouraging, showing enhanced sensitivity in the lower suPAR range, which is essential for use in preventive health settings.

During Q3, we identified further development opportunities to improve the product. Since the revised product is intended for the longevity market, it is crucial that it demonstrates low relative variance at the lower suPAR levels. We expect to have a finalized version of the product during Q4 and will communicate the next steps at that time, including the planned clinical work to establish its performance.

## Targeting the US longevity market

In addition to our collaboration with Sobi on suPARnostic® TurbiLatex, we continue to work with our US-based distributor, suPAR Health LLC, to bring suPAR testing to the US longevity and health management market. The initial implementation phase is underway, focusing on establishing suPARnostic® at selected laboratory sites.

In Q3, we aligned sales processes and shared plans with our distribution partner and the US team. The US longevity market operates with distinct sales channels and dynamics, partly due to the predominantly private healthcare system, where elements of the infrastructure are better suited to support the longevity market than in many other parts of the world.

# Financial highlights of Q1-Q3, 2025

## Key figures and ratios

<i>DKK ('000) unless otherwise stated</i>		Q1-Q3, 2025	Q1-Q3, 2024	% change	2024
<b>INCOME STATEMENT</b>	Net revenue	3,542	3,396	4%	4,897
	Other income	2,999	2,178	38%	2,245
	Gross profit/loss	4,674	4,029	16%	4,809
	Operating profit/loss	-7,904	-9,950	-21%	-14,560
	Financial income and expenses, net	-638	-482	32%	-620
	Profit/loss for the period before tax	-8,542	-10,432	-18%	-15,180
	Profit/loss for the period	-7,961	-9,918	-20%	-14,345
<b>BALANCE SHEET</b>	Assets	14,210	14,061	1%	17,660
	Equity	2,835	7,089	-60%	10,795
	Liabilities	11,375	6,972	63%	6,864
<b>CASH FLOW STATEMENT</b>	Cash flows from operating activities	-2,567	-8,596	-70%	-11,947
	Cash flows from investment activities	0	0	-	-4
	Cash flows from financing activities	-520	0	-100%	8,133
	Total cash flows	-3,088	-8,596	-64%	-3,819


<i>DKK unless otherwise stated</i>	Q1-Q3, 2025	Q1-Q3, 2024	% change	2024
Rate of return (%)	-162,41	-155,98	4%	-219.80
Share price, end of period	10.10	5.75	76%	10.60
Equity ratio (%)	20%	50%	-60%	57%
Employees, end of period (#)	7	10	-31%	10

# Financial highlights (continued)

## Revenue by product

DKK m, % of total


- TurbiLatex
- Quick Triage
- ELISA
- Other



## Revenue by geographic area

DKK m, % of total

- Europe
- North America
- ROW





**Note:** Regional split uses the United Nations geoscheme created by the UNSD.

# Financial highlights (continued)

## Recurring customers by segment

(# by end of period)

- Clinical routine
- Research



Thomas Krarup

*“After a slower second quarter, revenue improved in Q3, helping to balance overall performance for the year so far. The progress in Q3 reflects our focused commercial efforts and growing traction in the longevity and general health segments.”*

*We also attended key longevity conferences in the Baltics, which highlighted the rising interest in preventive health. The discussions confirmed the strong potential of suPARnostic® as an objective biomarker for identifying risk and monitoring lifestyle interventions – insights that support our long-term strategy in the longevity field.”*

Thomas Krarup, VP of Global Sales & Marketing

**Note:** Recurring customers are customers who have placed at least two orders over the last 12 months with an accumulated value of the orders of > 10,000 EUR. Clinical routine customers refer to customers using suPARnostic® products in routine patient/client handling and processes (e.g. a hospital using suPARnostic® for triage in the ED), while research customers refer to customers using suPARnostic® products for research purposes (e.g. a CRO using suPARnostic® to select patients in clinical trials).

# Contents

Summary	4
Management review	8
<b>Financial statements</b>	<b>13</b>
Statement by the Board and Executive Management	22

# Income Statement

<b>PROFIT &amp; LOSS</b> <i>Amounts in DKK ('000)</i>	Note	Q3, 2025	Q3, 2024	% change	Q1-Q3, 2025	Q1-Q3, 2024	% change	2024
<b>Net revenue</b>		<b>1,673</b>	<b>1,120</b>	<b>49%</b>	<b>3,542</b>	<b>3,396</b>	<b>4%</b>	<b>4,897</b>
Other income		0	1,880	-100%	2,999	2,178	38%	2,245
Cost of goods/services sold		-614	-591	4%	-1,868	-1,545	21%	-2,333
<b>Gross profit</b>		<b>1,059</b>	<b>2,408</b>	<b>-56%</b>	<b>4,674</b>	<b>4,029</b>	<b>16%</b>	<b>4,809</b>
Sales and distribution costs	<b>1</b>	-1,109	-1,793	-38%	-4,067	-6,301	-35%	-8,683
Research and development costs		-1,467	-1,980	-26%	-6,222	-5,017	24%	-6,908
Administrative costs		-516	-659	-22%	-2,288	-2,660	-14%	-3,778
<b>Operating loss</b>		<b>-2,033</b>	<b>-2,024</b>	<b>0%</b>	<b>-7,904</b>	<b>-9,950</b>	<b>-21%</b>	<b>-14,560</b>
Financial income		3	2	74%	44	20	124%	38
Financial expenses		-127	-169	-25%	-682	-502	36%	-658
<b>Loss before tax</b>		<b>-2,157</b>	<b>-2,191</b>	<b>-2%</b>	<b>-8,542</b>	<b>-10,432</b>	<b>-18%</b>	<b>-15,180</b>
Tax on profit/loss for the period	<b>2</b>	228	-37	-717%	581	514	13%	835
<b>Loss for the period</b>		<b>-1,930</b>	<b>-2,228</b>	<b>-13%</b>	<b>-7,961</b>	<b>-9,918</b>	<b>-20%</b>	<b>-14,345</b>
<b>Proposed distribution of loss</b>								
Retained profit		-1,930	-2,228	-13%	-7,961	-9,918	-20%	-14,345
<b>Total</b>		<b>-1,930</b>	<b>-2,228</b>	<b>-13%</b>	<b>-7,961</b>	<b>-9,918</b>	<b>-20%</b>	<b>-14,345</b>

# Balance Sheet

ASSETS						EQUITY AND LIABILITIES					
<i>Amounts in DKK ('000)</i>						<i>Amounts in DKK ('000)</i>					
	Note	Q3, 2025	Q3, 2024	% change	2024		Note	Q3, 2025	Q3, 2024	% change	2024
Rent deposit and other receivables		181	177	2%	181	Share capital		7,737	6,448	20%	7,737
<b>Fixed asset investments</b>	<b>3</b>	<b>181</b>	<b>177</b>	<b>2%</b>	<b>181</b>	Retained profit		-4,902	642	-864%	3,058
<b>Fixed assets</b>		<b>181</b>	<b>177</b>	<b>2%</b>	<b>181</b>	<b>Equity</b>	<b>4</b>	<b>2,835</b>	<b>7,089</b>	<b>-60%</b>	<b>10,795</b>
Finished goods and goods for resale		1,795	3,638	-51%	2,811	EIFO loan		3,634	5,300	-31%	4,273
<b>Inventories</b>		<b>1,795</b>	<b>3,638</b>	<b>-51%</b>	<b>2,811</b>	<b>Non-current liabilities</b>		<b>3,634</b>	<b>5,300</b>	<b>-31%</b>	<b>4,273</b>
Trade receivables		1,201	1,088	10%	1,208	EIFO loan		1,145	0	n/a	1,027
Other receivables		78	90	-13%	238	Trade payables		654	488	34%	281
Corporation tax receivable		1,416	1,507	-6%	835	Other liabilities		5,941	1,184	402%	1,283
Prepayments and accrued income		418	130	222%	179	<b>Current liabilities</b>		<b>7,740</b>	<b>1,672</b>	<b>-654%</b>	<b>2,591</b>
<b>Receivables</b>		<b>3,113</b>	<b>2,815</b>	<b>11%</b>	<b>2,459</b>	<b>Liabilities</b>		<b>11,374</b>	<b>6,972</b>	<b>63%</b>	<b>6,864</b>
<b>Cash and cash equivalents</b>		<b>9,120</b>	<b>7,431</b>	<b>23%</b>	<b>12,208</b>	<b>Equity and liabilities</b>		<b>14,210</b>	<b>14,061</b>	<b>1%</b>	<b>17,660</b>
<b>Current assets</b>		<b>14,029</b>	<b>13,884</b>	<b>1%</b>	<b>17,478</b>	<b>Contingencies</b>	<b>5</b>				
<b>Assets</b>		<b>14,210</b>	<b>14,061</b>	<b>1%</b>	<b>17,660</b>						

# Cash Flow Statement

<b>CASH FLOW</b> <i>Amounts in DKK ('000)</i>	<b>Note</b>	<b>Q3, 2025</b>	<b>Q3, 2024</b>	<b>% change</b>	<b>Q1-Q3, 2025</b>	<b>Q1-Q3, 2024</b>	<b>% change</b>	<b>2024</b>
Profit/loss for the period		-1,930	-2,228	-13%	-7,961	-9,918	-20%	-14,345
Reversed tax on profit/loss for the period		-228	37	-717%	-581	-514	13%	159
Corporation tax received		0	0	-	0	0	-	994
Change in inventory		577	595	-3%	1,016	1,500	-32%	2,328
Change in receivables		440	0	-	623	398	57%	-1,521
Change in current liabilities (ex bank and tax)		-1,352	291	-565%	4,336	-62	-7044%	438
<b>Cash flows from operating activity</b>		<b>-2,492</b>	<b>-1,305</b>	<b>91%</b>	<b>-2,567</b>	<b>-8,596</b>	<b>-70%</b>	<b>-11,947</b>
Purchase of financial assets		0	0	-	0	0	-	-4
<b>Cash flows from investing activity</b>		<b>0</b>	<b>0</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>-</b>	<b>-4</b>
Subscription of share capital		0	0	-	0	0	-	8,133
Loan		-266	0	-	-520	0	-	0
<b>Cash flows from financing activity</b>		<b>-266</b>	<b>0</b>	<b>-</b>	<b>-520</b>	<b>0</b>	<b>-</b>	<b>8,133</b>
<b>Change in cash and cash equivalents</b>		<b>-2,757</b>	<b>-1,305</b>	<b>111%</b>	<b>-3,088</b>	<b>-8,596</b>	<b>-64%</b>	<b>-3,819</b>
Cash and cash equivalents at 1 January		11,878	8,736	36%	12,208	16,027	-24%	16,027
<b>Cash and cash equivalents at end of period</b>		<b>9,120</b>	<b>7,431</b>	<b>23%</b>	<b>9,120</b>	<b>7,431</b>	<b>23%</b>	<b>12,208</b>
Specification of cash and cash equivalents at end of period:								
Cash and cash equivalents		9,120	7,431	23%	9,120	7,431	23%	12,208
<b>Cash and cash equivalents</b>		<b>9,120</b>	<b>7,431</b>	<b>23%</b>	<b>9,120</b>	<b>7,431</b>	<b>23%</b>	<b>12,208</b>

# Notes to the financial statements

## 1 Staff costs

<i>Amounts in DKK ('000) unless otherwise stated</i>	Q3, 2025	Q3, 2024	% change	2024
Average number of employees (#)	7	10	-31%	10
Sales & Marketing	809	1,289	-37%	6,322
Research & Development	528	568	-7%	2,786
Administration	314	328	-4%	1,607
<b>Total staff costs</b>	<b>1,650</b>	<b>2,185</b>	<b>-24%</b>	<b>10,715</b>

The remuneration for the Board of Directors and Executive Management are published annually in the Company's Remuneration Report in connection with the Annual Report.

## 2 Tax on profit/loss for the period

<i>Amounts in DKK ('000)</i>	Q3, 2025	Q3, 2024	% change	2024
Calculated tax on taxable income	228	-37	-717%	835
<b>Total</b>	<b>228</b>	<b>-37</b>	<b>-717%</b>	<b>835</b>

## 3 Fixed asset investments

<i>Amounts in DKK ('000)</i>	Q3, 2025	Q3, 2024	% change	2024
<i>Rent deposit and other receivables</i>				
Cost at 1 July 2025 / 2024	181	177	2%	177
Additions	0	0	-	4
<b>Cost at Q3 2025, Q3 2024, 2024</b>	<b>181</b>	<b>177</b>	<b>2%</b>	<b>181</b>
<b>Carrying amount of Q3 2025, Q3 2024, 2024</b>	<b>181</b>	<b>177</b>	<b>2%</b>	<b>181</b>

# Notes to the financial statements (continued)

## 4 Equity

<i>Amounts in DKK</i>	Q3, 2025	Q3, 2024	% change	2024
Share capital	7,737,064	6,447,554	20%	6,447,554
Retained profit	3,058,415	10,559,860	-71%	10,559,860
<b>Equity at 1 January</b>	<b>10,795,479</b>	<b>17,007,414</b>	<b>-37%</b>	<b>17,007,414</b>
Capital increase (share capital)	0	0	-	1,289,510
Capital increase (retained profit)	0	0	-	6,889,714
Cost regarding capital increase	0	0	-	-46,175
Proposed distribution of loss to retained profit	-7,960,563	-9,918,301	-20%	-14,344,981
<b>Equity at 30 September</b>	<b>2,834,916</b>	<b>7,089,113</b>	<b>-60%</b>	<b>10,795,482</b>

The Company's share capital consists of 7,737,064 shares of nom. 1 kr.

The Company has 2.585 treasury shares of nom. 1 kr. which equals 0.03% of the total share capital.

Under a resolution passed by the General Meeting, the Company may acquire treasury shares up to 10% of the share capital.

## 5 Contingencies

The Company has entered into an agreement for office rent with a notice of termination period of 5 months. There is a liability of DKK ('000) 130t.

Furthermore, the company has provided a guarantee in the form of a bank deposit of DKK ('000) 50 as security for all balances with Danske Bank.

## 6 Other external expenses

<i>Amounts in % of total expenses</i>	Q3, 2025	Q3, 2024	% change	2024
Sales expenses (incl. staff) in % of total expenses	35.87%	40.45%	-11%	44.83%
R&D expenses (incl. staff) in % of total expenses	47.45%	44.68%	6%	35.66%

# Active management & board warrant programs (as of 30 September 2025)

## 2019 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Jakob Knudsen (CEO)	56,439 (100%)	13,253 (23%)	8,465 (15%)	34,721 (62%)	34,721 (62%)
Thomas Krarup (VP S&M)	20,209 (100%)	10,102 (50%)	0 (0%)	10,107 (50%)	10,107 (50%)
Jesper Eugen-Olsen (CSO)	8,084 (100%)	5,051 (62%)	0 (0%)	3,033 (38%)	3,033 (38%)

### 2019 program details

- Strike price at 35 DKK
- 12% annual price increase from vesting date
- Expiry five years from vesting date

## 2022 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Other employees	12,500 (100%)	0 (0%)	0 (0%)	10,625 (85%)	12,500 (100%)
Patrik Dahlen (Chairman)	31,700 (100%)	0 (0%)	0 (0%)	22,190 (70%)	31,700 (100%)
V�alerie Soulier (BM)	9,510 (100%)	0 (0%)	0 (0%)	6,657 (70%)	9,510 (100%)
Josephine Baum (CFO)	30,000 (100%)	0 (0%)	0 (0%)	16,500 (55%)	30,000 (100%)

### 2022 program details

- Strike price at 129 DKK (other employees), 57.8 DKK (BoD), and 49.50 DKK (CFO)
- 12% annual price increase from vesting date
- Expiry five years from vesting date

## 2025 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Jakob Knudsen (CEO)	55,000 (100%)	0 (0%)	0 (0%)	6,875 (13%)	55,000 (100%)
Jesper Eugen-Olsen (CSO)	30,000 (100%)	0 (0%)	0 (0%)	3,750 (13%)	30,000 (100%)
Thomas Krarup (VP S&M)	25,000 (100%)	0 (0%)	0 (0%)	3,125 (13%)	25,000 (100%)
Josephine Baum (CFO)	15,000 (100%)	0 (0%)	0 (0%)	1,875 (13%)	15,000 (100%)
Other employees	5,000 (100%)	0 (0%)	0 (0%)	625 (13%)	5,000 (100%)

### 2025 program details

- Strike price at 13 DKK
- 12% annual price increase from vesting date
- Expiry five years from vesting date

**Note:** Numbers may not add up due to rounding. Mark Da Silva (resigned CFO) still has 16,431 outstanding warrants in the 2019 warrant program. A group of employees no longer employed by ViroGates still has 3,625 outstanding warrants in total in the 2022 program. The 2015 warrant program is not listed above, as all non-exercised warrants in the program have expired.

# Shareholdings of the board and management


Management (role)	Executive Management <sup>1</sup>	Management	PDMR <sup>2</sup>	Shares (#, end of Q3, 2025)	Shares (#, end of Q2, 2025)	Shares (#, end of last year)
Jakob Knudsen (CEO)	Yes	Yes	Yes	118,914	118,914	118,914
Josephine Baum Jørgensen (CFO)	No	Yes	Yes	1,200	1,200	1,200
Thomas Krarup (VP Sales & Marketing)	No	Yes	Yes	16,116	16,116	16,116
Jesper Eugen-Olsen (CSO)	No	Yes	No	300,539	301,416	294,615

Board (role)	PDMR <sup>2</sup>	Shares (#, end of Q3, 2025)	Shares (#, end of Q2, 2025)	Shares (#, end of last year)
Patrik Dahlén (Chairman)	Yes	10,570	10,570	10,570
Lars Kongsbak (Board member)	Yes	6,968	6,968	6,968
Valérie Soulier (Board member)	Yes	0	0	0

**Note:** 1) Executive management registered with the Danish Business Authority; 2) Person Discharging Managerial Responsibilities (permanent insider with access to all information).

# Trading windows for persons discharging managerial responsibilities

2025



**Trading windows for PDMRs**

- **Closed periods:** In accordance with MAR, ViroGates has a closed period of 30 days before the announcement of an interim financial report or a year-end report
- **Open periods:** ViroGates has an open period of six weeks after the announcement of an interim financial report or a year-end report (if an open period of a previous report overlaps a closed period of an upcoming report, the closed period applies)

**Note:** PDMRs can only trade shares during open trading windows given no insider information at the time of trading.

# Contents

Summary	4
Management review	8
Financial statements	14
<b>Statement by the Board and Executive Management</b>	<b>22</b>

# Statement by the Board of Directors and Executive Management

## Statement

Today, the Board of Directors and the Executive Management have discussed and approved the Interim Report of ViroGates A/S for the first nine months of 2025 (1 January – 30 September 2025).

The Interim Report has been created in accordance with IAS 34, Interim Financial Reporting as approved by the EU and additional disclosure requirements for companies listed on NASDAQ First North Denmark.

In our opinion, the financial statements give a true and fair view of the company's financial position at 30 September 2025 and of the results of the company's operations and cash flows for the financial period 1 January – 30 September 2025.

The management's review includes in our opinion a fair presentation of the matters dealt with in the report.

The Interim Report is unaudited.

*Birkerød, 6 November 2025*

### Executive Management

Jakob Ole Knudsen  
CEO

### Board of Directors

Patrik Dahlen  
(Chairman)

Valérie Soulier

Lars Kongsbak